FDA Panel Backs Pfizer Booster for 65 and Up, Rejects Broad Use.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      UNITED States. Food & Drug Administration ; PFIZER Inc. 001326495 PFE
    • Abstract:
      (Bloomberg) -- The Covid-19 vaccine booster shot proposed by Pfizer Inc. and BioNTech SE should be given to older Americans and those at high risk, a panel of expert advisers to the U.S. Food and Drug Administration said, rejecting a request for broader distribution. Moderna has also applied to the FDA for emergency authorization of a third dose booster, while the agency is still waiting for data backing an additional dose from Johnson & Johnson. [Extracted from the article]
    • Abstract:
      Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)